AI Article Synopsis
- The study investigates the effectiveness of transoral robotic surgery (TORS) and potential additional therapies for patients with oropharyngeal squamous cell carcinoma (SCC).
- Analyzing data from 314 patients over a follow-up period of about 3.3 years, the study finds high survival rates: 92% for locoregional recurrence-free, 90% for distant metastasis-free, 86% overall, and 94% cancer-specific survival rates at five years.
- Key factors affecting cancer survival include comorbidity, HPV status, the pathological classification of cancer, and the number of surgical attempts to remove cancer margins, indicating that more than two attempts increase the risk of recurrence and death.
Article Abstract
Background: This study presents oncologic outcomes after transoral robotic surgery (TORS) ± adjuvant therapy for oropharyngeal squamous cell carcinoma (SCC).
Methods: Three hundred fourteen patients undergoing TORS ± adjuvant therapy for oropharyngeal SCC from May 1, 2007, to May 31, 2015, are analyzed.
Results: Median follow-up was 3.3 years (interquartile range [IQR] 1.8-5.3 years; range 1 day to 9.3 years). Estimated locoregional recurrence-free survival, distant metastasis-free survival (DMFS), overall survival (OS), and cancer-specific survival (CSS) rates (95% confidence interval [CI] number still at risk) at 5 years after surgery were 92% (88-95; 92), 90% (86-94; 92), 86% (82-92; 98), and 94% (91-97; 98), respectively. Negative margins were achieved in 98% of cases. The adult comorbidity evaluation (ACE)-27 comorbidity index, human papillomavirus (HPV) status, pathologic N classification, and number of attempts to clear margins were associated with death due to cancer (P = .003, P = .002, P = .030, and P = .002, respectively).
Conclusion: The need to take ≥2 margins to achieve resection portends an increased risk of locoregional recurrence and death due to disease in oropharyngeal SCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.25055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lingual Artery Identification for Ligation in Neck Dissection and Transoral Surgery for Oropharyngeal Tumors.
Laryngoscope
January 2025
Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Objectives: Transoral robotic surgery (TORS) and transoral laser microsurgery (TOLM) plus neck dissection are viable alternatives to radiotherapy as a treatment modality in select cases of oropharyngeal squamous cell carcinoma. Many centers advocate for elective ligation of the feeding arteries at index neck dissection prior to TORS/TOLM to mitigate the risk of catastrophic perioperative hemorrhage. Although there are multiple cadaveric studies in the literature to identify the lingual artery at multiple points throughout its course, there are no studies on the intraoperative identification of the lingual artery for elective ligation prior to TORS/TOLM.
View Article and Find Full Text PDFA Novel Technique for Nasopharyngeal Stenosis Repair: Combined Transoral Robotic and Endonasal Approaches for Enhanced Visualization and Surgical Precision.
J Neurol Surg Rep
January 2025
Intent Medical Group, Department of Neurosciences, Northwest Community Hospital, Part of Endeavor Health, Arlington Heights, Illinois, United States.
Nasopharyngeal stenosis is a challenging condition characterized by a narrowed nasopharynx, leading to nasal congestion, impaired breathing, and recurrent sinus issues. In this report, we present a unique surgical approach that combines the use of both the Da Vinci Xi robot and a 70-degree nasal endoscope in a patient with a type II stenosis of the nasopharynx. The benefits of improved visualization, maneuverability, and precision of this novel combined approach are highlighted.
View Article and Find Full Text PDFSurgery for the Treatment of HPV-Negative Oropharyngeal Squamous Cell Carcinoma-A Systematic Review and Meta-Analysis.
Head Neck
January 2025
Department of Otolaryngology-Head and Neck Surgery, West Virginia University, Morgantown, West Virginia, USA.
Background: Human papillomavirus (HPV) negative oropharyngeal squamous cell carcinoma (OPSCC) is associated with worse survival when compared to HPV-positive OPSCC. Primary surgery is one option to intensify therapy in this high-risk group of patients. Unfortunately, the only randomized trial to explore this approach (RTOG 1221) failed to accrue and the role of primary surgery in the treatment of HPV-negative OPSCC remains unanswered.
View Article and Find Full Text PDFCirculating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease.
Eur Arch Otorhinolaryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Via Elio Chianesi 53, 00144, Rome, Italy.
Objectives: we evaluated the hypothesis that level of ctHPVDNA on the first postoperative day (POD-1); and at 15 days (POD-15) could be associated with the need for adjuvant therapy and the presence of recurrence.
Materials And Methods: this is a prospective observational study on biomarkers, focusing on the longitudinal monitoring of ctHPVDNA in a cohort of HPV-OPSCC patients undergoing TORS. Blood samples were collected according to the following schema: (1) pretreatment; (2) on first postoperative day (POD 1); and (3) at 15 days (POD 15).
Recent Advancements in Robotic-assisted Plastic Surgery Procedures: A Systematic Review.
Plast Reconstr Surg Glob Open
January 2025
Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust, London, United Kingdom.
Background: There has been a delayed, yet steady uptake of robotic-assisted surgery over the past decade within the field of plastic surgery. In an era of rapidly evolving scientific and technological development, there is a need for an update on the current literature for robotic-assisted plastic surgery procedures.
Methods: Searches were conducted across major databases, including MEDLINE, Embase, and Central for published literature from March 2023 to December 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!